Innate Pharma (IPHA) to Release Quarterly Earnings on Thursday

Innate Pharma (NASDAQ:IPHA) is projected to release its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Innate Pharma to post earnings of ($0.3492) per share and revenue of $1.96 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 26, 2026 at 9:00 AM ET.

Innate Pharma Stock Up 17.1%

IPHA opened at $1.37 on Tuesday. Innate Pharma has a 12-month low of $1.17 and a 12-month high of $2.63. The firm’s fifty day moving average price is $1.66 and its 200 day moving average price is $1.83.

Hedge Funds Weigh In On Innate Pharma

Several large investors have recently added to or reduced their stakes in IPHA. Millennium Management LLC acquired a new position in Innate Pharma in the fourth quarter worth $36,000. OLD Mission Capital LLC acquired a new stake in shares of Innate Pharma during the fourth quarter worth $50,000. Finally, Jane Street Group LLC bought a new position in shares of Innate Pharma in the 4th quarter worth about $162,000. 0.16% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

IPHA has been the subject of several research analyst reports. BTIG Research began coverage on shares of Innate Pharma in a research report on Thursday, March 12th. They issued a “buy” rating and a $8.00 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Innate Pharma in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Innate Pharma has an average rating of “Moderate Buy” and an average target price of $5.00.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.